Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at BMO Capital
May 1, 2019 12:59 PM EDTBMO Capital analyst Do Kim raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $126.00) while maintaining a Outperform rating following Q1 results.
The analyst commented, "We raise our Onpattro projections and target price to $128 from $126, as 1Q19 sales beat our and... More
Alnylam Pharma (ALNY) Tops Q1 EPS by 65c
May 1, 2019 8:06 AM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.42), $0.65 better than the analyst estimate of ($2.07). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $23.65 million.
2019 Updated Financial Guidance
Alnylam is updating its 2019 annual non-GAAP R&D... More
